The prescription drugs that ICER plans to assess next year include two PrEP combinations for HIV prevention, Celgene's ozanimod for relapsing multiple sclerosis, and Sage Therapeutics' two postpartum depression treatments, zuranolone and brexanolone, which is already on the market and sold under the name Zulresso.
You can see the complete list here.
Our June 2019 cover story was about Boston-based ICER (Institute for Clinical and Economic Review) and its increasingly important role as an arbiter of price and cost effectiveness for pharmaceuticals. Some patient groups (some with pharma backing or involvement) are critical of ICER and its use of QALYs.
ICER made the announcement about its "potential topics for assessments" earlier today. It had previously said it was going to review three acute migraine treatments in 2020: rimegepant, ubrogepant, and lasmiditan.
The FDA accepted Celgene's new drug application for ozanimod last month after giving the company a "refusal to file" letter last year. Ozanimod is seen as a potential blockbuster drug (sales in excess of $1 billion) although Novartis may mount a patent challenge that could cast a shadow on ozanimod's commercial future.
Gilead's Truvada is currently the only PrEP on the market. ICER's press release said it will assess two possible competitors in 2020, Descovy, which is also a Gilead product, and ViiV Healthcare's cabotegravir–rilpivirine combination. Descovy is FDA-approved for treatment of HIV but not as a preventive PrEP agent